These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17574889)

  • 21. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study.
    Plöckinger U; Reuter T
    Eur J Endocrinol; 2008 Apr; 158(4):467-71. PubMed ID: 18362292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pegvisomant decreases growth hormone to nothing].
    Krankenpfl J; 2004; 42(1-2):16-7. PubMed ID: 15116768
    [No Abstract]   [Full Text] [Related]  

  • 24. A simple, rapid immunometric assay for determination of functional and growth hormone-occupied growth hormone-binding protein in human serum.
    Fisker S; Frystyk J; Skriver L; Vestbo E; Ho KK; Orskov H
    Eur J Clin Invest; 1996 Sep; 26(9):779-85. PubMed ID: 8889440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
    Trainer PJ
    J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
    Jehle S; Reyes CM; Sundeen RE; Freda PU
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1588-93. PubMed ID: 15585549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
    Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
    Paisley AN; O'Callaghan CJ; Lewandowski KC; Parkinson C; Roberts ME; Drake WM; Monson JP; Trainer PJ; Randeva HS
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4635-40. PubMed ID: 16926249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating non-22-kilodalton growth hormone isoforms in acromegalic men before and after transsphenoidal surgery.
    Boguszewski CL; Johannsson G; Bengtsson BA; Johansson A; Carlsson B; Carlsson LM
    J Clin Endocrinol Metab; 1997 May; 82(5):1516-21. PubMed ID: 9141543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights from growth hormone receptor blockade.
    Muller AF; van der Lely AJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acromegaly and serum insulin-like growth factor I.
    Thorner MO
    Horm Res; 2004; 62 Suppl 1():34-6. PubMed ID: 15761230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.
    Bidlingmaier M; Freda PU
    Growth Horm IGF Res; 2010 Feb; 20(1):19-25. PubMed ID: 19818659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients.
    Galland F; Kamenicky P; Affres H; Reznik Y; Pontvert D; Le Bouc Y; Young J; Chanson P
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4957-61. PubMed ID: 16984995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
    Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
    Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
    Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.